Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation

Jean Bousquet, Cristina Barbara, Eric Bateman, Elisabeth Bel, Mike Bewick, Niels H. Chavannes, Alvaro A. Cruz, Tari Haahtela, Peter W. Hellings, Nikolai Khaltaev, Karin Lodrup Carlsen, Antonella Muraro, Carlos Robalo Cordeiro, Jose Rosado-Pinto, Boleslaw Samolinski, Timo Strandberg, Arunas Valiulis, Arzu Yorgancioglu, Torsten Zuberbier the AIRWAYS-ICPs working group
European Respiratory Journal 2016 47: 1028-1033; DOI: 10.1183/13993003.01856-2015
Jean Bousquet
1University Hospital, Montpellier, France
2MACVIA-LR, Contre les Maladies Chroniques pour un VIeillissement Actif en Languedoc Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
3INSERM, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, U1168, Paris, and UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
5EIP on AHA Commitment for Action
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean Bousquet
  • For correspondence: jean.bousquet@orange.com
Cristina Barbara
5EIP on AHA Commitment for Action
6PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Bateman
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
7Department of Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Bel
8Department of Respiratory Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands
9ERS Past President, European Respiratory Society
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Bewick
10Deputy National Medical Director, NHS England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niels H. Chavannes
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
11Dept of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
12International Primary Care Respiratory Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvaro A. Cruz
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
13ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and GARD Executive Committee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tari Haahtela
5EIP on AHA Commitment for Action
14Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter W. Hellings
15Laboratory of Clinical Immunology, Dept of Microbiology and Immunology, KU Leuven, Leuven, Belgium
16EAACI, European Academy of Allergy and Clinical Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolai Khaltaev
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Lodrup Carlsen
5EIP on AHA Commitment for Action
17Dept of Paediatrics, Oslo University Hospital, Oslo, Norway
18Faculty of Medicine, University of Oslo, Institute of Clinical Medicine, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonella Muraro
16EAACI, European Academy of Allergy and Clinical Immunology
19Dept of Women and Child Health, Food Allergy Referral Centre Veneto Region, Padua General University Hospital, Padua, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Robalo Cordeiro
20Centre of Pneumology, Coimbra University Hospital, Coimbra, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Rosado-Pinto
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
21Serviço de Imunoalergologia, Hospital da Luz, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boleslaw Samolinski
5EIP on AHA Commitment for Action
22Dept of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timo Strandberg
23Dept of Paediatrics, Universities of Helsinki and Oulu, Finland
24European Union Geriatric Medicine Society, EUGMS
30Helsinki University Central Hospital, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arunas Valiulis
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
25Vilnius University Clinic of Children's Diseases, Vilnius, Lithuania
26European Academy of Pediatrics (EAP/UEMS-SP)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arzu Yorgancioglu
4GARD, Global Alliance against Chronic Respiratory Diseases (GARD)
5EIP on AHA Commitment for Action
27Dept of Pulmonology, Celal Bayar University, Manisa, Turkey
28Turkish Thoracic Society
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Zuberbier
29Allergy-Centre-Charité at the Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
31Secretary General of the Global Allergy and Asthma European Network (GA2LEN)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

AIRWAYS-ICPs is a European Union initiative on multi-sectoral care pathways for chronic respiratory diseases http://ow.ly/Yndtw

Chronic respiratory diseases (CRDs) are major non-communicable diseases (NCDs) [1, 2] that induce a significant burden. Asthma often occurs along the life cycle from early childhood, affecting 30 million children and adults under 45 years of age in Europe [3]. Chronic obstructive pulmonary disease (COPD) has an estimated annual death rate of over 3 million people globally [1, 2]. The annual direct and indirect costs in the 28 European Union (EU) countries due to COPD or asthma are estimated at 48 billion euros and 34 billion euros respectively [3]. Rhinitis occurs in over 100 million people in Europe, and indirect costs are enormous [4]. Asthma is a common risk factor for COPD [5, 6]. CRDs impact ageing and should be prevented, recognised and managed across the life cycle to promote active and healthy ageing (AHA). There is an urgent need to act globally.

European Innovation Partnerships (EIPs) aim to enhance EU competitiveness and tackle societal challenges through research and innovation. To tackle the potential of ageing in the EU, the European Commission, within its Innovation Union policy, launched the EIP on AHA (between the Directorate General for Health and Food Safety (DG Santé) and Directorate General for Communications Networks, Content and Technology (DG CONNECT)) [7]. The B3 Action Plan promotes integrated care models for chronic diseases, including the use of remote monitoring.

The initiative AIRWAYS-ICPs (integrated care pathways for airway diseases) [8] has been approved by the EIP on AHA as the model of chronic diseases of the B3 Action Plan. It is a Research Demonstration Project of the World Health Organization's Global Alliance against Chronic Respiratory Diseases (GARD) [1]. AIRWAYS-ICPs was initiated in 2013 by the WHO Collaborating Centre of Montpellier and the EIP on AHA Reference Site MACVIA-LR (Contre les MAladies Chroniques Pour un VIeillissement Actif en Languedoc-Roussillon, France) led by the Région Languedoc-Roussillon (France) [9].

The GARD action plan was the model of AIRWAYS-ICPs (figure 1).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

AIRWAYS-ICPs (integrated care pathways for airway diseases) interactions between the European Union and World Health Organization. NGO: nongovernmental organisation; GO: governmental organisation, MOH: Ministry of Health; GARD: Global Alliance against Chronic Respiratory Diseases; NCD: non-communicable disease; EIP: European Innovation Partnership; AHA: active and healthy ageing; DG Santé: Directorate General for Health and Food Safety; DG CONNECT: Directorate General for Communications Networks, Content and Technology; MeDALL WP10: Mechanisms of the Development of Allergy workpackage 10; DG Research: Directorate-General for Research and Innovation.

Objectives

The aim of AIRWAYS-ICPs is to launch a collaboration to develop practical multisectoral care pathways (ICPs) to reduce the burden of chronic respiratory diseases, their mortality and multimorbidity. AIRWAYS-ICPs proposes a feasible, achievable and manageable project from science to guidelines and policies using existing networks and stakeholders committed to the Action Plan B3 of the EIP on AHA and GARD [1, 2]. It is implemented in European countries and regions, as part of the EIP on AHA, and is scaled up globally with GARD.

Stakeholders

AIRWAYS-ICPs activities are being implemented by a group of 450 members in 70 countries. Members also include those of previous initiatives such as ARIA (Allergic Rhinitis and its Impact on Asthma; initiated in collaboration with WHO) [10] and GARD [1, 2]. The majority of members have been working together since 1999. The GA2LEN (Global Allergy and Asthma European Network, Sixth Framework Programme) network of excellence centres of allergy and asthma [11] and members of EIP on AHA commitments for action are also involved. All stakeholders needed for the implementation of an action plan at the national and local levels actively participate. Scientific societies also participate in the project.

Implementation of the AIRWAYS-ICPs action plan

The action plan was devised by a group of 450 members and implemented in 2013 [8]. Activities are proposed in a logical framework from existing tools to novel information communication technology (ICT) tools and innovative health systems in order to provide an integrated solution for CRDs across the life cycle. The model of CRD can then be used for the health promotion of AHA and management of CRDs in older adults.

  • Proposing a common framework of care pathways (ICPs) for CRDs to facilitate comparability and trans-national initiatives targeted to all populations according to culture, health systems and income [12]: AIRWAYS-ICPs is participating in the development of a repository that is currently being developed by the EU and that will be available in December 2015. This repository will include good practices in CRDs such as National Institute for Health and Care Excellence (NICE; UK) guidance, national programmes for CRDs [13], asthma, COPD or allergy [14–16], guidelines for asthma, COPD or allergic rhinitis [10, 17–20], and ICPs.

  • Developing a strategy for low-resource settings based on existing WHO initiatives such as the WHO Package of Essential Noncommunicable disease [21] and the essential list of drugs, as well as validated primary management strategies in low- and middle-income countries [22].

  • Aiding risk stratification in chronic disease patients with a common strategy. AIRWAYS-ICPs has developed a simple stratification algorithm for asthma control and severity (following a 2009 WHO meeting) which can be extended to all chronic diseases unifying the classification of the diseases for clinical, research and public health use [23–25].

  • Defining important questions on CRDs in older adults. There are no specific recommendations for CRDs in older adults and a research activity is ongoing to better understand asthma, COPD and their multimorbidities in old age.

  • Developing multisectoral care pathways for CRDs and their multimorbidities across the life cycle, implementing emerging technologies for individualised and predictive medicine. Within the past four decades, an epidemic of allergic diseases and asthma has been observed globally in children and adults. The expected epidemic wave of asthma and rhinitis in older adults is an insufficiently recognised problem. In Europe, over 20% of adults suffer from allergic rhinitis and over 5% from asthma. These patients are now reaching the age of 65 years and a new health problem in old age people will be to understand, detect and manage these patients who also suffer from NCD multimorbididy and polymedication. There is an urgent need for a simple tool which would allow individualised and predictive medicine. AIRWAYS-ICPs is tackling this expected health problem, based on systems medical principles, in accordance with guidelines proposed by the European Commission (www.casym.eu) using the MACVIA-ARIA Sentinel NetworK (MASK). A common language is being used at the patient, pharmacist and physician levels using tablets and cell phones (figure 2).

  • A first project directly linked with the activities of the WHO Collaborating Centre on rhinitis and asthma was initiated in 2013 and has been completed [10, 26–30]. MASK proposes the study of symptoms of patients suffering from allergic symptoms during the pollen season (rhinitis and asthma) in order to make them sentinels for the onset and severity of the pollen season. Patients are geolocalised and evaluate their symptoms by visual analogue scale using a cell phone with a touch screen or internet. A clinical decision support system will be finalised in December 2015. A care pathway from the patient to health care professionals has been built (figure 2) and a clinical decision support system will be available in December 2015.

  • The system has been extended to persistent rhinitis and asthma, and a pulmonary function test using cell phones is currently being tested (available mid 2016). This may be of interest in all countries to screen for bronchial obstruction (asthma and COPD) by patients or at primary healthcare centres.

  • The application is available in 15 languages from the App store (iOS) and Google play (Android). It is free for patients and, due to the simplicity of the tool, it can be used in developed and many developing countries (if a smart phone is available).

  • Embedding the concept of frailty into CRDs and proposing an operational AHA questionnaire developed by the Reference Site Network of the EIP on AHA using WHO Disability Assessment Schedule 2.0 and quality-of-life questionnaires [31, 32]. Unrecognised CRDs can be detected in frail elderly patients [33]. Optimising treatment and integrated care services of frail COPD patients with multimorbidities and polypharmacy improves certain health outcomes [34].

  • Scaling up strategies in Europe and beyond. The scaling up strategy has been clearly defined and approved by AIRWAYS-ICPs members. It follows the EIP-AHA recommendations on a five-step framework: 1) what to scale up: 1-1) databases of good practices; 1-2) assessment of viability of the scaling up of good practices; 1-3) classification of good practices for local replication; and 2) how to scale up: 2-1) facilitating partnerships for scaling up; 2-2) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. Scaling up will take place within and beyond Europe with GARD [35–40].

  • Strengthening the WHO NCD Action Plan. AIRWAYS-ICPs is in line with the WHO NCD Action Plan since it aims to reduce the preventable and avoidable burden of morbidity, mortality and disability by means of multisectoral collaboration and cooperation at national, regional and global levels.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Care pathways for rhinitis and asthma multimorbidity across the life cycle. OTC: over-the-counter. Reproduced from [26] with permission from the publisher.

Conclusions

AIRWAYS-ICPs is expected in the short term to reduce morbidity, and improve education and work and in the long term to promote AHA [41]. AIRWAYS-ICPs has strategic relevance to the EU Health Strategy and the WHO NCD Action Plan (2013–2020), adding value to existing public health knowledge.

Acknowledgements

AIRWAYS-ICPs working group: Adcock I, Addis A, Agache I, Agusti A, Alonso A, Annesi Maesano I, Anto JM, Bachert C, Baena-Cagnani C, Bai C, Baigenzhin A, Barnes PJ, Beck L, Bedbrook A, Benezet O, Bennoor KS, Benson M, Bernabeu-Wittel M, Bindslev Jensen C, Blain H, Blasi F, Bonini M, Bonini S, Boulet LP, Bourdin A, Bourret R, Bousquet PJ, Brightling CE, Briggs A, Brozek J, Buhl R, Bush A, Caimmi D, Calderon M, Calverley P, Camargos P, Camuzat T, Canonica GW, Carlsen KH, Casale TB, Cazzola M, Cepeda Sarabia AM, Cesario A, Chen YZ, Chkhartishvili E, Chiron R, Chuchalin A, Chung KF, Cox L, Crooks G, Crooks MG, Custovic A, Dahl R, Dahlen SE, De Blay F, Dedeu T, Deleanu D, Demoly P, Devillier P, Didier A, Dinh Xuan AT, Djukanovic R, Dokic D, Douagui H, Dubakiene R, Eglin S, Elliot F, Emuzyte R, Fabbri L, Fink-Wagner A, Fletcher M, Fokkens WJ, Fonseca J, Franco A, Frith P, Furber A, Gaga M, Gamkrelidze A, Garcia Aymerich J, González-Díaz S, Gouzi F, Garcés J, Guzmán MA, Harrison D, Hayot M, Heaney L, Heinrich J, Hooper J, Humbert M, Hyland M, Iaccarino G, Jakovenko D, Jardim J, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Joos G, Jung KS, Kalayci O, Karunanithi S, Keil T, Kolek V, Kowalski M, Kull I, Kuna P, Kvedariene V, Le LT, Louis R, MacNee W, Mair A, Manning P, Manuel Keenoy ME, Majer I, Masjedi MR, Melén E, Melo Gomes E, Menzies-Gow A, Mercier G, Mercier J, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Molimard M, Momas I, Montilla-Santana A, Morais Almeida M, Morgan M, N'Diaye M, Nafti S, Nekam, Neou A, Nicod L, O'Hehir R, Ohta K, Paggiaro P, Palkonen S, Palmer S, Papadopoulos NG, Papi A, Passalacqua G, Pavord I, Pedersen S, Pigearias B, Plavec D, Postma DS, Price D, Rabe KF, Radier Pontal F, Redon J, Rennard S, Roberts J, Robine JM, Roca J, Roche N, Rodenas F, Roggeri A, Rolland C, Ryan D, Sanchez-Borges M, Schünemann HJ, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Small I, Sola-Morales O, Sooronbaev T, Stelmach R, Sterk PJ, Stiris T, Sud P, Tellier V, To T, Todo Bom A, Triggiani M, Valenta R,Valero AL, Valovirta E, Vandenplas O, Van Ganse E, Vasankari T, Vestbo J, Vezzani G, Viegi G, Visier L, Vogelmeier C, Vontetsianos T, Wagstaff R, Wallaert B, Wahn U, Whalley B, Wickman M, Williams D, Wilson N, Yawn BP, Yiallouros P, Yusuf O, Zar HJ, Zhong N, Zidarn M.

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

  • Received November 9, 2015.
  • Accepted November 9, 2015.
  • Copyright ©ERS 2016

References

  1. ↵
    1. Bousquet J,
    2. Dahl R,
    3. Khaltaev N
    . Global alliance against chronic respiratory diseases. Allergy 2007; 62: 216–223.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Bousquet J,
    2. Khaltaev N. eds
    . Global surveillance, prevention and control of Chronic Respiratory Diseases. A comprehensive approach. Geneva, World Health Organization, 2007.
  3. ↵
    1. Gibson GJ,
    2. Loddenkemper R,
    3. Lundback B, et al.
    Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J 2013; 42: 559–563.
    OpenUrlFREE Full Text
  4. ↵
    1. Zuberbier T,
    2. Lotvall J,
    3. Simoens S, et al.
    Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy 2014; 69: 1275–1279.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Svanes C,
    2. Sunyer J,
    3. Plana E, et al.
    Early life origins of chronic obstructive pulmonary disease. Thorax 2010; 65: 14–20.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Perret JL,
    2. Dharmage SC,
    3. Matheson MC, et al.
    The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. Am J Respir Crit Care Med 2013; 187: 42–48.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Bousquet J,
    2. Michel J,
    3. Standberg T, et al.
    The European Innovation Partnership on Active and Healthy Ageing: the European Geriatric Medicine introduces the EIP on AHA Column. Eur Geriatr Med 2014; 5: 361–362.
    OpenUrlCrossRef
  8. ↵
    1. Bousquet J,
    2. Addis A, et al.
    Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 2014; 44: 304–323.
    OpenUrlFREE Full Text
  9. ↵
    1. Bousquet J,
    2. Bourquin C,
    3. Augé P, et al.
    MACVIA-LR Reference Site of the European Innovation Partnership on Active and Healthy Ageing. Eur Geriatr Med 2014; 5: 406–415.
    OpenUrlCrossRef
  10. ↵
    1. Bousquet J,
    2. Schunemann HJ,
    3. Samolinski B, et al.
    Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–1062.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bousquet J,
    2. Burney PG,
    3. Zuberbier T, et al.
    GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’. Allergy 2009; 64: 969–977.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Selroos O,
    2. Kupczyk M,
    3. Kuna P, et al.
    National and regional asthma programmes in Europe. Eur Respir Rev 2015. 24: 474–483.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Portuguese National Programme for Respiratory Diseases 2012–2016. Portuguese Directorate General of Health. 2012.
  14. ↵
    1. Haahtela T,
    2. Tuomisto LE,
    3. Pietinalho A, et al.
    A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663–670.
    OpenUrlAbstract/FREE Full Text
    1. Haahtela T,
    2. von Hertzen L,
    3. Makela M, et al.
    Finnish Allergy Programme 2008-2018--time to act and change the course. Allergy 2008; 63: 634–645.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Kinnula VL,
    2. Vasankari T,
    3. Kontula E, et al.
    The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality. Prim Care Respir J 2011; 20: 178–183.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Boulet LP,
    2. FitzGerald JM,
    3. Levy ML, et al.
    A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. Eur Respir J 2012; 39: 1220–1229.
    OpenUrlAbstract/FREE Full Text
    1. Reddel HK,
    2. Bateman ED,
    3. Becker A, et al.
    A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015; 46: 622–639.
    OpenUrlAbstract/FREE Full Text
    1. Vestbo J,
    2. Hurd SS,
    3. Agusti AG, et al.
    Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187: 347–365.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Chung KF,
    2. Wenzel SE,
    3. Brozek JL, et al.
    International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Cancer, diabetes, heart disease and stroke, chronic respiratory disease. Geneva, World Health Organization, 2010.
  19. ↵
    1. Fairall L,
    2. Bateman E,
    3. Cornick R, et al.
    Innovating to improve primary care in less developed countries: towards a global model. BMC Innovations 2015. 1: 196–203.
    OpenUrlCrossRef
  20. ↵
    1. Bousquet J,
    2. Mantzouranis E,
    3. Cruz AA, et al.
    Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926–938.
    OpenUrlCrossRefPubMedWeb of Science
    1. Bousquet J,
    2. Anto JM,
    3. Demoly P, et al.
    Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol 2012; 158: 216–231.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Bousquet J,
    2. Jorgensen C,
    3. Dauzat M, et al.
    Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. Curr Pharm Des 2014; 20: 5928–5944.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Bousquet J,
    2. Schunemann HJ,
    3. Fonseca J, et al.
    MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy 2015; 70: 1372–1392.
    OpenUrlCrossRefPubMed
    1. Bousquet J,
    2. Schunemann HJ,
    3. Bousquet PJ, et al.
    How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy 2011; 66: 765–774.
    OpenUrlCrossRefPubMed
    1. Bousquet J,
    2. Schunemann HJ,
    3. Zuberbier T, et al.
    Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper. Allergy 2010; 65: 1212–1221.
    OpenUrlCrossRefPubMedWeb of Science
    1. Brozek JL,
    2. Baena-Cagnani CE,
    3. Bonini S, et al.
    Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008; 63: 38–46.
    OpenUrlPubMed
  23. ↵
    1. Brozek JL,
    2. Bousquet J,
    3. Baena-Cagnani CE, et al.
    Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466–476.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Samolinski B,
    2. Raciborski F,
    3. Bousquet J, et al.
    Development of Senioral Policy in Poland. Eur Geriatr Med 2015; 7: in press.
  25. ↵
    1. Bousquet J,
    2. Kuh D,
    3. Bewick M, et al.
    Operational definition of active and healthy ageing (AHA): Report of the meeting held in Montpellier October 21,22-2012. Eur Geriatr Med 2015; 6: 196–200.
    OpenUrlCrossRef
  26. ↵
    1. Bertens LC,
    2. Reitsma JB,
    3. van Mourik Y, et al.
    COPD detected with screening: impact on patient management and prognosis. Eur Respir J 2014; 44: 1571–1578.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Hernandez C,
    2. Alonso A,
    3. Garcia-Aymerich J, et al.
    Integrated care services: lessons learned from the deployment of the NEXES project. Int J Integr Care 2015; 15: e006.
    OpenUrlPubMed
  28. ↵
    1. Bousquet J,
    2. Grouse L,
    3. Zhong N
    . The fight against chronic respiratory diseases in the elderly: the European Innovation Partnership on Active and Healthy Aging and beyond. J Thorac Dis 2015; 7: 108–110.
    OpenUrlPubMed
    1. Lodrup Carlsen KC,
    2. Haahtela T,
    3. Carlsen KH, et al.
    Integrated Allergy and Asthma Prevention and Care: Report of the MeDALL/AIRWAYS ICPs Meeting at the Ministry of Health and Care Services, Oslo, Norway. Int Arch Allergy Immunol 2015; 167: 57–64.
    OpenUrlCrossRefPubMed
    1. Bousquet J,
    2. Tanasescu CC,
    3. Camuzat T, et al.
    Impact of early diagnosis and control of chronic respiratory diseases on active and healthy ageing. A debate at the European Union Parliament. Allergy 2013; 68: 555–561.
    OpenUrlCrossRefPubMed
    1. Samolinski B,
    2. Fronczak A,
    3. Kuna P, et al.
    Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy 2012; 67: 726–731.
    OpenUrlCrossRefPubMedWeb of Science
    1. Samolinski B,
    2. Fronczak A,
    3. Wlodarczyk A, et al.
    Council of the European Union conclusions on chronic respiratory diseases in children. Lancet 2012; 379: e45–e46.
    OpenUrlPubMed
  29. ↵
    1. Bousquet J,
    2. Anto JM,
    3. Berkouk K, et al.
    Developmental determinants in non-communicable chronic diseases and ageing. Thorax 2015; 70: 595–597.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Kupczyk M,
    2. Haahtela T,
    3. Cruz AA, et al.
    Reduction of asthma burden is possible through National Asthma Plans. Allergy 2010; 65: 415–419.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 47 Issue 4 Table of Contents
European Respiratory Journal: 47 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
Jean Bousquet, Cristina Barbara, Eric Bateman, Elisabeth Bel, Mike Bewick, Niels H. Chavannes, Alvaro A. Cruz, Tari Haahtela, Peter W. Hellings, Nikolai Khaltaev, Karin Lodrup Carlsen, Antonella Muraro, Carlos Robalo Cordeiro, Jose Rosado-Pinto, Boleslaw Samolinski, Timo Strandberg, Arunas Valiulis, Arzu Yorgancioglu, Torsten Zuberbier
European Respiratory Journal Apr 2016, 47 (4) 1028-1033; DOI: 10.1183/13993003.01856-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
Jean Bousquet, Cristina Barbara, Eric Bateman, Elisabeth Bel, Mike Bewick, Niels H. Chavannes, Alvaro A. Cruz, Tari Haahtela, Peter W. Hellings, Nikolai Khaltaev, Karin Lodrup Carlsen, Antonella Muraro, Carlos Robalo Cordeiro, Jose Rosado-Pinto, Boleslaw Samolinski, Timo Strandberg, Arunas Valiulis, Arzu Yorgancioglu, Torsten Zuberbier
European Respiratory Journal Apr 2016, 47 (4) 1028-1033; DOI: 10.1183/13993003.01856-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Objectives
    • Stakeholders
    • Implementation of the AIRWAYS-ICPs action plan
    • Conclusions
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Long-term outcome of co-infection of COVID-19 and TB
  • Leukocyte telomere length: personalised medicine for fibrotic ILD?
  • An attack of asthma is not an attack of the heart
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society